Psychemedics (PMDI) 10-K 27 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000806517
Entity Registrant Name	PSYCHEMEDICS CORP
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	1-13738
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-1701987
Entity Address, Address Line One	289 Great Road
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
City Area Code	978
Local Phone Number	206-8220
Title of 12(b) Security	Common stock. $0.005 par value
Trading Symbol	PMD
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 26,900,000
Entity Common Stock, Shares Outstanding		5,684,647
Auditor Firm ID	243
Auditor Name	BDO USA, LLP
Auditor Location	Boston, Massachusetts

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 4,750	$ 1,992
Accounts receivable, net of allowance for doubtful accounts of $87 and $89 at December 31, 2022 and 2021, respectively	3,739	4,116
Prepaid expenses and other current assets	1,136	1,499
Income tax receivable	339	2,678
Total Current Assets	9,964	10,285
Property and equipment:
Computer software	4,648	4,521
Office furniture and equipment	2,247	2,195
Laboratory equipment	16,013	16,005
Leasehold improvements	3,629	3,629
Property, Plant and Equipment, Gross, Ending Balance	26,537	26,350
Accumulated depreciation and amortization	(21,964)	(19,659)
Property, Plant and Equipment, Net, Total	4,573	6,691
Other assets	823	864
Deferred tax assets	691	160
Operating lease right-of-use assets	2,681	3,552
Total Assets	18,732	21,552
Current Liabilities:
Accounts payable	448	994
Accrued expenses	3,939	3,188
Current portion of long-term debt	294	664
Current portion of operating lease liabilities	1,037	984
Total Current Liabilities	5,718	5,830
Long-term debt	305	599
Long-term portion of operating lease liabilities	1,938	2,880
Total Liabilities	7,961	9,309
Commitments and Contingencies (Note 9)
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.005 par value; 50,000 shares authorized 6,349 shares and 6,257 shares issued at December 31, 2022 and 2021, respectively, 5,681 shares outstanding and 5,589 shares outstanding at December 31, 2022 and 2021, respectively	32	31
Additional paid-in capital	34,275	33,478
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated deficit	(11,820)	(9,550)
Accumulated other comprehensive loss	(1,634)	(1,634)
Total Shareholders' Equity	10,771	12,243
Total Liabilities and Shareholders' Equity	$ 18,732	$ 21,552

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Allowance for doubtful accounts	$ 87	$ 89
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized (in shares)	873	873
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares issued (in shares)	6,349	6,257
Common stock, shares outstanding (in shares)	5,681	5,589
Treasury stock, shares (in shares)	668	668

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	$ 25,240	$ 24,909	$ 21,360
Cost of revenues	15,949	14,645	16,474
Gross profit	9,291	10,264	4,886
Operating Expenses:
General & administrative	5,857	6,126	6,095
Marketing & selling	3,191	2,799	3,577
Research & development	1,326	1,130	1,280
Total Operating Expenses	10,374	10,055	10,952
Operating (loss) income	(1,083)	209	(6,066)
Other Income (Expense):
Gain on forgiveness of PPP Loan	0	2,181	0
Settlements	0	(3,150)	0
Other income (expense)	43	(61)	(140)
Total Other Income (Expense)	43	(1,030)	(140)
Net loss before provision for (benefit from) income taxes	(1,040)	(821)	(6,206)
Provision for (benefit from) income taxes	44	(156)	(2,347)
Net loss	(1,084)	(665)	(3,859)
Other Comprehensive Loss:
Foreign currency translation, net of taxes	0	0	(10)
Total Comprehensive Loss	$ (1,084)	$ (665)	$ (3,869)
Basic net loss per share (in dollars per share)	$ (0.19)	$ (0.12)	$ (0.70)
Diluted net loss per share (in dollars per share)	(0.19)	(0.12)	(0.70)
Dividends declared, per share (in dollars per share)	$ 0.21	$ 0.05	$ 0.18
Weighted average common shares outstanding:
Basic (in shares)	5,626	5,549	5,524
Diluted (in shares)	5,626	5,549	5,524

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2019	6,185		668
Balance at Dec. 31, 2019	$ 31,000	$ 32,249,000	$ (10,082,000)	$ (3,754,000)	$ (1,624,000)	$ 16,820,000
Shares issued – vested (in shares)	20
Tax withholding related to vested shares from employee stock plans	$ 0	(9,000)	0	0	0	(9,000)
Stock compensation expense		563,000				563,000
Cash dividends declared	0	0	0	(993,000)	0	(993,000)
Net loss	0	0	0	(3,859,000)	0	(3,859,000)
Foreign currency translation, net of taxes	$ 0	0	$ 0	0	(10,000)	(10,000)
Balance (in shares) at Dec. 31, 2020	6,205		668
Balance at Dec. 31, 2020	$ 31,000	32,803,000	$ (10,082,000)	(8,606,000)	(1,634,000)	12,512,000
Shares issued – vested (in shares)	51		0
Tax withholding related to vested shares from employee stock plans	$ 0	(72,000)	$ 0	0	0	(72,000)
Stock compensation expense	0	743,000	0	0	0	743,000
Cash dividends declared	0	0	0	(279,000)	0	(279,000)
Net loss	$ 0	0	$ 0	(665,000)	0	(665,000)
Foreign currency translation, net of taxes						0
Exercise of stock options (in shares)	1		0
Exercise of stock options	$ 0	4,000	$ 0	0	0	4,000
Balance (in shares) at Dec. 31, 2021	6,257		668
Balance at Dec. 31, 2021	$ 31,000	33,478,000	$ (10,082,000)	(9,550,000)	(1,634,000)	12,243,000
Shares issued – vested (in shares)	91		0
Tax withholding related to vested shares from employee stock plans	$ 0	(78,000)	$ 0	0	0	(78,000)
Stock compensation expense	0	872,000	0	0	0	872,000
Cash dividends declared	0	0	0	(1,186,000)	0	(1,186,000)
Net loss	$ 0	0	$ 0	(1,084,000)	0	(1,084,000)
Foreign currency translation, net of taxes						$ 0
Exercise of stock options (in shares)	1		0			1
Exercise of stock options	$ 0	4,000	$ 0	0	0	$ 4,000
Shares issued – vested	$ 1	(1)
Balance (in shares) at Dec. 31, 2022	6,349		668
Balance at Dec. 31, 2022	$ 32,000	$ 34,275,000	$ (10,082,000)	$ (11,820,000)	$ (1,634,000)	$ 10,771,000

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Dividends declared, per share (in dollars per share)	$ 0.21	$ 0.05	$ 0.18

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (1,084)	$ (665)	$ (3,859)
Adjustments to reconcile net loss to net cash provided by operating activities:
Forgiveness of PPP loan	0	(2,181)	0
Depreciation and amortization	2,367	2,784	2,691
ROU asset amortization	949	906	935
Deferred income taxes	(531)	(371)	(339)
Loss on sale of fixed assets	0	0	94
Stock compensation expense	872	743	563
Changes in operating assets and liabilities:
Accounts receivable	377	(760)	424
Prepaid expenses and other current assets	363	(585)	392
Income tax receivable	2,339	(183)	(2,013)
Accounts payable	(546)	417	(281)
Operating lease liabilities	(967)	(1,078)	(914)
Accrued expenses	751	1,387	(1,776)
Net cash provided by (used in) operating activities	4,890	414	(4,083)
Cash flows from investing activities:
Proceeds from sale of fixed assets	0	0	140
Other assets	(21)	(38)	(7)
Purchases of property and equipment and capitalized software development costs	(187)	(182)	(991)
Net cash used in investing activities	(208)	(220)	(858)
Cash flows from financing activities:
Cash dividends paid	(1,186)	(279)	(993)
Proceeds from stock options and tax withholding related to vested shares from employee stock plans	(74)	(68)	(9)
Payments of equipment financing	(664)	(688)	(678)
Net cash (used in) provided by financing activities	(1,924)	(1,035)	501
Effect of exchange rate changes on cash	0	0	(10)
Net increase (decrease) in cash	2,758	(841)	(4,450)
Cash, beginning of year	1,992	2,833	7,283
Cash, end of year	4,750	1,992	2,833
Supplemental disclosures of cash flow information:
Cash paid for income taxes	0	405	249
Cash paid for interest	33	50	75
Cash paid for operating leases	1,044	1,151	1,038
Right-of-use assets acquired through operating leases	78	172	2,346
Non-cash investing and financing activities:
Purchases of equipment through accounts payable and accrued liabilities		0	241
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities:
Proceeds from long term det	$ 0	$ 0	$ 2,181

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Company Overview Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company’s customers include Fortune 500 COVID- 19 The outbreak of coronavirus (“COVID- 19” 19 19’s The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on March 27, 2020, December 2020, 19. 19 December 31, 2021, December 31, 2020, 2020 Liquidity and Management s Plans At December 31, 2022, 12 may not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities at the date of purchase of 90 December 31, 2022, 2021, Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software 3 5 Office furniture and equipment 3 7 Laboratory equipment 5 7 Leasehold improvements Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 2020, not December 31, 2022, Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three five December 31, 2022, 2021, 2022, 2021 2020, may Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2022, December 31, 2021, 2022, 2021 2020, December 31, 2022, $62 five December 31, 2027 Allowance for Doubtful Accounts The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not not Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 Year Ended December 31, 2022 2021 2020 Consolidated Revenue: Testing $ 21,608 $ 21,894 $ 19,068 Shipping / Collection (hair) 3,476 2,847 2,174 Other 156 168 118 Total Revenue $ 25,240 $ 24,909 $ 21,360 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred as they are typically not Research and Development Expenses The Company expenses all research and development costs as incurred. Contingencies Loss contingencies from legal proceedings and claims may Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, Income Taxes Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may not not not no Significant Customers and Concentration of Credit Risk The Company had no customers that represented 10% December 31, 2022, 2021, 2020, one December 31, 2022 2021, Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation Stock Compensation 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by statements of operations account is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenues $ 63 $ 63 $ 50 General & administrative 626 503 380 Marketing & selling 113 114 74 Research & development 70 63 59 Total stock compensation $ 872 $ 743 $ 563 See Note 7 Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2022 2021 2020 Weighted average common shares outstanding, basic 5,626 5,549 5,524 Dilutive common equivalent shares - - - Weighted average common shares outstanding, assuming dilution 5,626 5,549 5,524 For the years ended December 31, 2022, 2021 2020, not Fair Value Measurements The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms. Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. Segment Reporting The Company manages its operations as one 14 Recently Adopted Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 first 2023. 2016 13 not

Note 3 - Accounts Receivable

Note 3 - Accounts Receivable	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	3. The Company maintains an allowance for uncollectible accounts receivable based on management’s assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands): As of December 31, 2022 2021 Balance, beginning of period $ 89 $ 37 Provision for doubtful accounts 9 55 Write-offs ( 11 ) ( 3 ) Balance, end of period $ 87 $ 89

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued expenses consist of the following (in thousands): As of December 31, 2022 2021 Accrued compensation and employee benefits $ 442 $ 507 Accrued vacation expense 409 373 Accrued taxes 771 200 Accrued shipping expense 338 488 Accrued legal settlement 1,150 1,150 Other accrued expenses 829 470 Total Accrued Expenses $ 3,939 $ 3,188

Note 5 - Income Taxes

Note 5 - Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. The income tax provision consists of the following (in thousands): Year Ended December 31, 2022 2021 2020 Current Federal $ 552 $ 131 $ ( 2,006 ) State 23 84 ( 2 ) Total Current 575 215 ( 2,008 ) Federal ( 959 ) ( 704 ) ( 13 ) State 428 333 ( 326 ) Total Deferred ( 531 ) ( 371 ) ( 339 ) Income Tax Provision $ 44 $ ( 156 ) $ ( 2,347 ) A reconciliation of the effective rate with the federal statutory rate is as follows: Year Ended December 31, 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 12.0 % 10.4 % 4.4 % Permanent differences (0.4% ) 47.6 % 0.0 % Stock based compensation 0.5 % 1.4 % (0.4% ) Federal R&D Credits 8.9 % 0.0 % 1.6 % Foreign taxes, net of federal benefit 0.0 % (10.9% ) (2.2% ) Difference in tax rate for carryback claim 0.0 % 0.0 % 13.4 % Increase/(decrease) in valuation reserve (46.2% ) (50.5% ) 0.0 % Effective tax rate -4.2 % 19.0 % 37.8 % The change in effective tax rate from 2021 2022 2021 2021 2022. December 31, 2022, December 31, 2022, 2030 2040, not December 31, 2022, 2013 2022 2022, The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands): As of December 31, 2022 2021 Deferred Tax Assets Allowance for doubtful accounts $ 21 $ 21 Accrued expenses 414 129 Stock-based compensation 381 325 R&D tax credits 1,086 1,083 Operating lease 701 944 Capitalized research expenses 404 - NOL carryforward 72 219 Gross Deferred Tax Assets 3,079 2,721 Valuation Allowance ( 895 ) ( 414 ) Deferred Tax Assets After Valuation Allowance 2,184 2,307 Deferred Tax Liabilities Excess of tax over book depreciation and amortization ( 783 ) ( 1,249 ) Prepaid expenses ( 78 ) ( 61 ) Operating lease ( 632 ) ( 837 ) Gross Deferred Tax Liabilities ( 1,493 ) ( 2,147 ) Net Deferred Tax Assets $ 691 $ 160 Income taxes are recorded in accordance with FASB ASC Topic 740, 740” not not 2019 12 January 1, 2021, no ASC 740 two first not second 50% may may not December 31, 2022, 2021, The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may may December 31, 2022, 2021 2020 not

Note 6 - Preferred Stock

Note 6 - Preferred Stock	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Preferred Stock [Text Block]	6. The Board of Directors has the authority to designate authorized preferred shares in one no

Note 7 - Stock-based Awards

Note 7 - Stock-based Awards	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. The 2006 2006 ten May 2021, 2006 December 31, 2022, 2006 The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs and options vest over a period of two four 2016 09 2016, no On April 4, 2022, two thousand May 20, 2022, August 12, 2022, The following table represents all shares granted by the Company under the 2006 three Grant Date Type Shares Fair Value August 12, 2022 SUA 18 $ 6.65 May 20, 2022 SUA 126 $ 6.51 April 4, 2022 SUA 2 $ 7.04 May 13, 2021 SUA 116 $ 6.55 March 16, 2021 SUA 2 $ 7.04 January 25, 2021 SUA 2 $ 5.54 December 16, 2020 SUA 5 $ 4.71 November 11, 2020 Options 40 $ 1.13 November 11, 2020 SUA 190 $ 4.07 ( 1 The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 November 11, 2020, No December 31, 2022, 2021. December 31, 2020, December 31, 2022, 2021 2020, A summary of the Company’s stock option activity is as follows (in thousands, except price per share): Number of Weighted Average Weighted Aggregate (2) Outstanding, December 31, 2021 574 $ 14.23 6.1 years $ 100 Granted - $ - Exercised (1 ) $ 4.07 Forfeited (1 ) $ 4.07 Canceled (64 ) $ 15.03 Outstanding, December 31, 2022 508 $ 14.19 5.1 years $ 25 Exercisable, December 31, 2022 467 $ 14.70 4.9 years $ 14 ( 2 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 December 31, 2022, 2021 A summary of the Company’s stock unit award activity is as follows (in thousands, except price per share): Number of Shares Weighted Average Grant-Date Fair Value per Share (3) Outstanding & Unvested, December 31, 2021 224 $ 5.48 Granted 146 $ 6.53 Converted to common stock ( 90 ) $ 6.33 Cancelled ( 12 ) $ 6.29 Forfeited ( 30 ) $ 6.26 Outstanding & Unvested, December 31, 2022 238 $ 6.10 ( 3 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. The fair value of stock unit award vesting was $548 thousand, $296 thousand and $274 thousand for the years ended December 31, 2022, 2021, 2020, December 31, 2022, 2021, 2020, As of December 31, 2022, 2006 December 31, 2022, The Board of Directors approved the accelerated vesting of 35 thousand SUAs to certain directors upon retirement from the Board of the Company during the year ended December 31, 2022. December 31, 2022.

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	8. The Psychemedics Corporation 401 “401 401 21 401 may, not zero zero December 31, 2022, 2021 2020,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through December 2026. 2022, 2021 2020, 10 Contingencies In the normal course of business, we are subject to contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product liability, contractual claims and tax matters. We recognize accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. These estimates are subject to uncertainties that are difficult to predict and, as such, actual results could vary from these estimates. Settlements On December 6, 2021, No. 2:20 06624 In the binding MOU, the parties agreed to settle this matter for a payment by the Company of $1.2 million in exchange for the dismissal of the California Lawsuit and a customary release of liability, subject only to final court approval and the process described below. Factoring in that process, the Company estimates that the settlement funds will be dispersed in the second 2023, Although the Company believes that the allegations in the California Lawsuit lack merit, it agreed at a mediation to enter into the binding MOU to settle the claims in the California Lawsuit in order to avoid potentially significant legal fees, other expenses, and management time that would have to be devoted to protracted litigation in California regarding its wage and hour laws. The foregoing was also impacted in part by new California case law in February 2021 June 9, 2017. The MOU assumes class certification for purposes of the settlement only. The settlement amount of $1.2 not 2004. December 31, 2022, 2021

Note 10 - Operating Leases

Note 10 - Operating Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Operating Leases The Company has five no not not The weighted average discount rate used for leases as of December 31, 2022, December 31, 2022, twelve December 31, 2022, 2021, Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of December 31, 2022, 2023 $ 1,134 2024 1,061 2025 553 2026 460 Total lease payments 3,208 Less: interest ( 233 ) Present value of lease liabilities $ 2,975 Current operating lease liabilities $ 1,037 Long-term operating lease liabilities 1,938 Total $ 2,975

Note 11 - Debt and Other Financ

Note 11 - Debt and Other Financing Arrangements	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	11. Debt and Other Financing Arrangements On March 20, 2014, March 23, 2021, 30 60 first 2020 2021. December 31, 2022. Under the Equipment Loan Arrangement, the Company executed notes on various dates between March 24, 2014, December 4, 2019 2022 2021, December 31, 2022, December 31, 2022, December 31, 2022, On May 1, 2020, May 4, 2022. one 1% In July 2021, 100% 2021 The annual principal repayment requirements for debt obligations as of December 31, 2022, 2023 $ 294 2024 305 Long-term debt from equipment financing 599 Less current portion of long-term debt from equipment financing (294 ) Long-term debt from equipment financing, net of current portion $ 305

Note 12 - Other Income (Expense

Note 12 - Other Income (Expense)	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	12. Interest expense for the year ended December 31, 2022, 2021, 2020 December 31, 2022, 2021, 2020.

Note 13 - Business Segment Repo

Note 13 - Business Segment Reporting	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	13. The Company manages its operations as one Year Ended December 31, 2022 2021 2020 Consolidated Revenue: United States $ 24,509 $ 23,584 $ 19,486 International 731 1,325 1,874 Total Revenue $ 25,240 $ 24,909 $ 21,360

Note 14 - Subsequent Event

Note 14 - Subsequent Event	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	14. On March 21, 2023, April 10, 2023 March 31, 2023.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities at the date of purchase of 90 December 31, 2022, 2021,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software 3 5 Office furniture and equipment 3 7 Laboratory equipment 5 7 Leasehold improvements Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 2020, not December 31, 2022,
Research, Development, and Computer Software, Policy [Policy Text Block]	Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three five December 31, 2022, 2021, 2022, 2021 2020, may
Other Assets [Policy Text Block]	Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2022, December 31, 2021, 2022, 2021 2020, December 31, 2022, $62 five December 31, 2027
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not not
Revenue [Policy Text Block]	Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 Year Ended December 31, 2022 2021 2020 Consolidated Revenue: Testing $ 21,608 $ 21,894 $ 19,068 Shipping / Collection (hair) 3,476 2,847 2,174 Other 156 168 118 Total Revenue $ 25,240 $ 24,909 $ 21,360 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred as they are typically not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses The Company expenses all research and development costs as incurred.
Contingent Liability Reserve Estimate, Policy [Policy Text Block]	Contingencies Loss contingencies from legal proceedings and claims may
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, Income Taxes
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may not not not no
Major Customers, Policy [Policy Text Block]	Significant Customers and Concentration of Credit Risk The Company had no customers that represented 10% December 31, 2022, 2021, 2020, one December 31, 2022 2021,
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation Stock Compensation 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by statements of operations account is as follows (in thousands): Year Ended December 31, 2022 2021 2020 Cost of revenues $ 63 $ 63 $ 50 General & administrative 626 503 380 Marketing & selling 113 114 74 Research & development 70 63 59 Total stock compensation $ 872 $ 743 $ 563 See Note 7
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2022 2021 2020 Weighted average common shares outstanding, basic 5,626 5,549 5,524 Dilutive common equivalent shares - - - Weighted average common shares outstanding, assuming dilution 5,626 5,549 5,524 For the years ended December 31, 2022, 2021 2020, not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms.
Basis of Presentation and Consolidation, Policy [Policy Text Block]	Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting The Company manages its operations as one 14
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 first 2023. 2016 13 not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer software 3 5 Office furniture and equipment 3 7 Laboratory equipment 5 7 Leasehold improvements Lesser of estimated useful life or lease term
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2022 2021 2020 Consolidated Revenue: Testing $ 21,608 $ 21,894 $ 19,068 Shipping / Collection (hair) 3,476 2,847 2,174 Other 156 168 118 Total Revenue $ 25,240 $ 24,909 $ 21,360
Schedule of Stock Based Compensation Expense [Table Text Block]	Year Ended December 31, 2022 2021 2020 Cost of revenues $ 63 $ 63 $ 50 General & administrative 626 503 380 Marketing & selling 113 114 74 Research & development 70 63 59 Total stock compensation $ 872 $ 743 $ 563
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	2022 2021 2020 Weighted average common shares outstanding, basic 5,626 5,549 5,524 Dilutive common equivalent shares - - - Weighted average common shares outstanding, assuming dilution 5,626 5,549 5,524

Note 3 - Accounts Receivable (T

Note 3 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	As of December 31, 2022 2021 Balance, beginning of period $ 89 $ 37 Provision for doubtful accounts 9 55 Write-offs ( 11 ) ( 3 ) Balance, end of period $ 87 $ 89

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of December 31, 2022 2021 Accrued compensation and employee benefits $ 442 $ 507 Accrued vacation expense 409 373 Accrued taxes 771 200 Accrued shipping expense 338 488 Accrued legal settlement 1,150 1,150 Other accrued expenses 829 470 Total Accrued Expenses $ 3,939 $ 3,188

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2022 2021 2020 Current Federal $ 552 $ 131 $ ( 2,006 ) State 23 84 ( 2 ) Total Current 575 215 ( 2,008 ) Federal ( 959 ) ( 704 ) ( 13 ) State 428 333 ( 326 ) Total Deferred ( 531 ) ( 371 ) ( 339 ) Income Tax Provision $ 44 $ ( 156 ) $ ( 2,347 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2022 2021 2020 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 12.0 % 10.4 % 4.4 % Permanent differences (0.4% ) 47.6 % 0.0 % Stock based compensation 0.5 % 1.4 % (0.4% ) Federal R&D Credits 8.9 % 0.0 % 1.6 % Foreign taxes, net of federal benefit 0.0 % (10.9% ) (2.2% ) Difference in tax rate for carryback claim 0.0 % 0.0 % 13.4 % Increase/(decrease) in valuation reserve (46.2% ) (50.5% ) 0.0 % Effective tax rate -4.2 % 19.0 % 37.8 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2022 2021 Deferred Tax Assets Allowance for doubtful accounts $ 21 $ 21 Accrued expenses 414 129 Stock-based compensation 381 325 R&D tax credits 1,086 1,083 Operating lease 701 944 Capitalized research expenses 404 - NOL carryforward 72 219 Gross Deferred Tax Assets 3,079 2,721 Valuation Allowance ( 895 ) ( 414 ) Deferred Tax Assets After Valuation Allowance 2,184 2,307 Deferred Tax Liabilities Excess of tax over book depreciation and amortization ( 783 ) ( 1,249 ) Prepaid expenses ( 78 ) ( 61 ) Operating lease ( 632 ) ( 837 ) Gross Deferred Tax Liabilities ( 1,493 ) ( 2,147 ) Net Deferred Tax Assets $ 691 $ 160

Note 7 - Stock-based Awards (Ta

Note 7 - Stock-based Awards (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Grant Date Type Shares Fair Value August 12, 2022 SUA 18 $ 6.65 May 20, 2022 SUA 126 $ 6.51 April 4, 2022 SUA 2 $ 7.04 May 13, 2021 SUA 116 $ 6.55 March 16, 2021 SUA 2 $ 7.04 January 25, 2021 SUA 2 $ 5.54 December 16, 2020 SUA 5 $ 4.71 November 11, 2020 Options 40 $ 1.13 November 11, 2020 SUA 190 $ 4.07
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Average Weighted Aggregate (2) Outstanding, December 31, 2021 574 $ 14.23 6.1 years $ 100 Granted - $ - Exercised (1 ) $ 4.07 Forfeited (1 ) $ 4.07 Canceled (64 ) $ 15.03 Outstanding, December 31, 2022 508 $ 14.19 5.1 years $ 25 Exercisable, December 31, 2022 467 $ 14.70 4.9 years $ 14
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Shares Weighted Average Grant-Date Fair Value per Share (3) Outstanding & Unvested, December 31, 2021 224 $ 5.48 Granted 146 $ 6.53 Converted to common stock ( 90 ) $ 6.33 Cancelled ( 12 ) $ 6.29 Forfeited ( 30 ) $ 6.26 Outstanding & Unvested, December 31, 2022 238 $ 6.10

Note 10 - Operating Leases (Tab

Note 10 - Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2023 $ 1,134 2024 1,061 2025 553 2026 460 Total lease payments 3,208 Less: interest ( 233 ) Present value of lease liabilities $ 2,975 Current operating lease liabilities $ 1,037 Long-term operating lease liabilities 1,938 Total $ 2,975

Note 11 - Debt and Other Fina_2

Note 11 - Debt and Other Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	2023 $ 294 2024 305 Long-term debt from equipment financing 599 Less current portion of long-term debt from equipment financing (294 ) Long-term debt from equipment financing, net of current portion $ 305

Note 13 - Business Segment Re_2

Note 13 - Business Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2022 2021 2020 Consolidated Revenue: United States $ 24,509 $ 23,584 $ 19,486 International 731 1,325 1,874 Total Revenue $ 25,240 $ 24,909 $ 21,360

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Income Tax Benefit CARES Act	$ 2,600	$ 200
Cash and Cash Equivalents, at Carrying Value, Total	$ 1,992		$ 4,750

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Cash Equivalents, at Carrying Value, Total	$ 0	$ 0
Depreciation, Depletion and Amortization, Nonproduction, Total	2,400	2,800	$ 2,700
Property, Plant and Equipment, Net, Ending Balance	4,573	$ 6,691
Finite-Lived Intangible Asset, Expected Amortization, Year One	62
Finite-Lived Intangible Asset, Expected Amortization, Year Two	62
Finite-Lived Intangible Asset, Expected Amortization, Year Three	62
Finite-Lived Intangible Asset, Expected Amortization, Year Four	62
Finite-Lived Intangible Asset, Expected Amortization, Year Five	62
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	$ 109
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	508	574	588
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	0	0	0
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers	1	1	1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage	11%	12%
Patents [Member]
Amortization, Total	$ 62	$ 62	$ 62
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Legal Cost Capitalized	$ 1,100	1,100
Legal Cost Capitalized, Amortization	500	400
Legal Cost Capitalized, Net	600		700
Capitalized Software and Equipment [Member]
Property, Plant and Equipment, Net, Ending Balance	500
Software Development [Member]
Software Development Cost Capitalized	127	99
Amortization, Total	$ 282	$ 421	$ 293
Software Development [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Software Development [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)	12 Months Ended
	Dec. 31, 2022
Minimum [Member] | Office Equipment [Member]
Property, plant and equipment, useful life (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	5 years
Minimum [Member] | Computer Software, Intangible Asset [Member]
Property, plant and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant and equipment, useful life (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	7 years
Maximum [Member] | Computer Software, Intangible Asset [Member]
Property, plant and equipment, useful life (Year)	5 years

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	$ 25,240	$ 24,909	$ 21,360
Testing [Member]
Revenues	21,608	21,894	19,068
Shipping/Collection (Hair) [Member]
Revenues	3,476	2,847	2,174
Other Revenue [Member]
Revenues	$ 156	$ 168	$ 118

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock compensation expense	$ 872	$ 743	$ 563
Cost of Sales [Member]
Stock compensation expense	63	63	50
General and Administrative Expense [Member]
Stock compensation expense	626	503	380
Selling and Marketing Expense [Member]
Stock compensation expense	113	114	74
Research and Development Expense [Member]
Stock compensation expense	$ 70	$ 63	$ 59

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Weighted average common shares outstanding, basic (in shares)	5,626	5,549	5,524
Dilutive common equivalent shares (in shares)	0	0	0
Weighted average common shares outstanding, assuming dilution (in shares)	5,626	5,549	5,524

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance, beginning of period	$ 89	$ 37
Provision for doubtful accounts	9	55
Write-offs	(11)	(3)
Balance, end of period	$ 87	$ 89

Note 4 - Accrued Expenses - Sum

Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued compensation and employee benefits	$ 442	$ 507
Accrued vacation expense	409	373
Accrued taxes	771	200
Accrued shipping expense	338	488
Accrued legal settlement	1,150	1,150
Other accrued expenses	829	470
Total Accrued Expenses	$ 3,939	$ 3,188

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	$ 0
Tax Credit Carryforward, Amount	0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	1,300
Operating Loss Carryforwards, Subject to Expiration	1,200
Operating Loss Carryforwards, Not Subject to Expiration	100
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Tax Credit Carryforward, Amount	$ 1,400
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total	12%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	8.30%

Note 5 - Income Taxes - Summary

Note 5 - Income Taxes - Summary of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Federal	$ 552	$ 131	$ (2,006)
State	23	84	(2)
Total Current	575	215	(2,008)
Federal	(959)	(704)	(13)
State	428	333	(326)
Total Deferred	(531)	(371)	(339)
Income Tax Provision	$ 44	$ (156)	$ (2,347)

Note 5 - Income Taxes - Reconci

Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Federal statutory rate	21%	21%	21%
State income taxes, net of federal benefit	12%	10.40%	4.40%
Permanent differences	(0.40%)	47.60%	0%
Stock based compensation	0.50%	1.40%	(0.40%)
Federal R&D Credits	8.90%	0%	1.60%
Foreign taxes, net of federal benefit	0%	(10.90%)	(2.20%)
Difference in tax rate for carryback claim	0%	0%	13.40%
Increase/(decrease) in valuation reserve	(46.20%)	(50.50%)	0%
Effective tax rate	(4.20%)	19%	37.80%

Note 5 - Income Taxes - Compone

Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets
Allowance for doubtful accounts	$ 21	$ 21
Accrued expenses	414	129
Stock-based compensation	381	325
R&D tax credits	1,086	1,083
Operating lease	701	944
Capitalized research expenses	404	0
NOL carryforward	72	219
Gross Deferred Tax Assets	3,079	2,721
Valuation Allowance	(895)	(414)
Deferred Tax Assets After Valuation Allowance	2,184	2,307
Deferred Tax Liabilities
Excess of tax over book depreciation and amortization	(783)	(1,249)
Prepaid expenses	(78)	(61)
Operating lease	(632)	(837)
Gross Deferred Tax Liabilities	(1,493)	(2,147)
Net Deferred Tax Assets	$ 691	$ 160

Note 7 - Stock-based Awards (De

Note 7 - Stock-based Awards (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands					12 Months Ended
	Aug. 12, 2022	May 20, 2022	Apr. 04, 2022	Nov. 11, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2006	May 31, 2021	Jan. 31, 2019
Share Price (in dollars per share)				$ 1.13	$ 4.90	$ 7.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 3.47
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value					$ 548	$ 296	$ 274
Conversion of Stock, Amount Issued					650	$ 501	$ 115
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 1,200
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 3 months 18 days
Stock Unit Award [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	18	126	2,000		146
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 6.53	$ 6.55	$ 4.89
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)					35
Share-Based Payment Arrangement, Accelerated Cost					$ 230
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 4.07
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				45%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				0.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				4%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					2 years
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				5 years 9 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					4 years
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				6 years 3 months
Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					183				1,600	1,200
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					1,032

Note 7 - Stock-based Awards - S

Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
November 11, 2020 [Member]
Shares granted (in shares) | shares	40
Fair value per share (in dollars per share) | $ / shares	$ 1.13
Shares granted (in shares) | shares	40
Fair value per share (in dollars per share) | $ / shares	$ 1.13
Stock Unit Award [Member] | August 12, 2022 [Member]
Shares granted (in shares) | shares	18
Fair value per share (in dollars per share) | $ / shares	$ 6.65	[1]
Shares granted (in shares) | shares	18
Fair value per share (in dollars per share) | $ / shares	$ 6.65	[1]
Stock Unit Award [Member] | May 20, 2022 [Member]
Shares granted (in shares) | shares	126
Fair value per share (in dollars per share) | $ / shares	$ 6.51	[1]
Shares granted (in shares) | shares	126
Fair value per share (in dollars per share) | $ / shares	$ 6.51	[1]
Stock Unit Award [Member] | April 4, 2022 [Member]
Shares granted (in shares) | shares	2
Fair value per share (in dollars per share) | $ / shares	$ 7.04	[1]
Shares granted (in shares) | shares	2
Fair value per share (in dollars per share) | $ / shares	$ 7.04	[1]
Stock Unit Award [Member] | May 13, 2021 [Member]
Shares granted (in shares) | shares	116
Fair value per share (in dollars per share) | $ / shares	$ 6.55	[1]
Shares granted (in shares) | shares	116
Fair value per share (in dollars per share) | $ / shares	$ 6.55	[1]
Stock Unit Award [Member] | March 16, 2021 [Member]
Shares granted (in shares) | shares	2
Fair value per share (in dollars per share) | $ / shares	$ 7.04	[1]
Shares granted (in shares) | shares	2
Fair value per share (in dollars per share) | $ / shares	$ 7.04	[1]
Stock Unit Award [Member] | January 25, 2021 [Member]
Shares granted (in shares) | shares	2
Fair value per share (in dollars per share) | $ / shares	$ 5.54	[1]
Shares granted (in shares) | shares	2
Fair value per share (in dollars per share) | $ / shares	$ 5.54	[1]
Stock Unit Award [Member] | December 16, 2020 [Member]
Shares granted (in shares) | shares	5
Fair value per share (in dollars per share) | $ / shares	$ 4.71	[1]
Shares granted (in shares) | shares	5
Fair value per share (in dollars per share) | $ / shares	$ 4.71	[1]
Stock Unit Award [Member] | November 11, 2020 [Member]
Shares granted (in shares) | shares	190
Fair value per share (in dollars per share) | $ / shares	$ 4.07
Shares granted (in shares) | shares	190
Fair value per share (in dollars per share) | $ / shares	$ 4.07
[1]The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on May 3, 2019, have a fair value of $2.99 per share based on the $10.60 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 41% volatility, 2.4% interest rate and a 3.9% dividend yield rate. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0%dividend yield rate. No options were granted during fiscal year ended December 31, 2021. For options granted during fiscal years ended December 31, 2020, and 2019, the weighted average grant date fair values were $3.47, and $3.40,respectively. For SUAs granted during fiscal years ended December 31, 2021, 2020 and 2019, the weighted average grant date fair values were $6.55, $4.89, and $12.01, respectively.

Note 7 - Stock-based Awards -_2

Note 7 - Stock-based Awards - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021
Outstanding (in shares)	574
Outstanding, weighted average exercise price (in dollars per share)	$ 14.23
Outstanding, weighted average remaining contractual life (Year)	5 years 1 month 6 days		6 years 1 month 6 days
Outstanding, aggregate intrinsic value	$ 25	[1]	$ 100
Exercised (in shares)	(1)
Exercised, weighted average exercise price (in dollars per share)	$ 4.07
Forfeited (in shares)	(1)
Forfeited, weighted average exercise price (in dollars per share)	$ 4.07
Canceled (in shares)	(64)
Canceled (in dollars per share)	$ 15.03
Outstanding (in shares)	508		574
Outstanding, weighted average exercise price (in dollars per share)	$ 14.19		$ 14.23
Exercisable (in shares)	467
Exercisable, weighted average exercise price (in dollars per share)	$ 14.70
Exercisable, weighted average remaining contractual life (Year)	4 years 10 months 24 days
Exercisable, aggregate intrinsic value	$ 14
[1]The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2021, and 2020 was $7.02 and $5.09, respectively.

Note 7 - Stock-based Awards - N

Note 7 - Stock-based Awards - Nonvested Award Activity (Details) - Stock Unit Award [Member] - $ / shares shares in Thousands					12 Months Ended
		Aug. 12, 2022	May 20, 2022	Apr. 04, 2022	Dec. 31, 2022
Outstanding & Unvested at beginning of period (in shares)					224
Outstanding & Unvested at beginning of period, weighted average price per share (in dollars per share)	[1]				$ 5.48
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		18	126	2,000	146
Granted, weighted average price per share (in dollars per share)	[1]				$ 6.53
Converted to common stock (in shares)					(90)
Converted to common stock, weighted average price per share (in dollars per share)	[1]				$ 6.33
Cancelled (in shares)					(12)
Cancelled, weighted average price per share (in dollars per share)	[1]				$ 6.29
Forfeited (in shares)					(30)
Forfeited, weighted average price per share (in dollars per share)	[1]				$ 6.26
Outstanding & Unvested at end of period (in shares)					238
Outstanding & Unvested at end of period, weighted average price per share (in dollars per share)	[1]				$ 6.10
[1]Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0	$ 198

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions		12 Months Ended
	Dec. 06, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Lease, Expense		$ 1	$ 1.1	$ 1.1
Enma Sagastume v. Psychemedics Corporation [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 1.2
Loss Contingency Accrual, Ending Balance			$ 1.2

Note 10 - Operating Leases (Det

Note 10 - Operating Leases (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Lease, Weighted Average Discount Rate, Percent	3.80%
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years 2 months 12 days
Operating Lease, Expense	$ 1	$ 1.1	$ 1.1

Note 10 - Operating Leases - Ma

Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 1,134
2024	1,061
2025	553
2026	460
Total lease payments	3,208
Less: interest	(233)
Present value of lease liabilities	2,975
Current operating lease liabilities	1,037	$ 984
Long-term operating lease liabilities	1,938	$ 2,880
Total	$ 2,975

Note 11 - Debt and Other Fina_3

Note 11 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Thousands				12 Months Ended			68 Months Ended
	May 01, 2020	Dec. 02, 2019	Oct. 30, 2017	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 04, 2019
Interest Expense, Total				$ 32	$ 49	$ 75
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 2,100			0	0	$ 2,181
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member]
Interest Expense, Total		$ 16,000		32
Debt Instrument, Term (Month)		60 months
Debt Instrument, Interest Rate, Stated Percentage		3.79%
Proceeds from Issuance of Long-term Debt, Total							$ 12,200
Repayments of Long-term Debt, Total				700	$ 700
Long-Term Debt, Total				$ 600
Long-Term Debt, Weighted Average Interest Rate, over Time				3.70%
Debt, Weighted Average Interest Rate				3.80%
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate			1.75%

Note 11 - Debt and Other Fina_4

Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Less current portion of long-term debt from equipment financing	$ (294)	$ (664)
Long-term debt from equipment financing, net of current portion	305	$ 599
Equipment Loan Arrangement [Member]
2023	294
2024	305
Long-term debt from equipment financing	599
Less current portion of long-term debt from equipment financing	(294)
Long-term debt from equipment financing, net of current portion	$ 305

Note 12 - Other Income (Expen_2

Note 12 - Other Income (Expense) (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Interest Expense, Total	$ 32	$ 49	$ 75
Interest Income, Other	$ 0	$ 0

Note 13 - Business Segment Re_3

Note 13 - Business Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2022
Number of Operating Segments	1

Note 13 - Business Segment Re_4

Note 13 - Business Segment Reporting - Revenue by Major Source (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	$ 25,240	$ 24,909	$ 21,360
UNITED STATES
Revenues	24,509	23,584	19,486
Non-US [Member]
Revenues	$ 731	$ 1,325	$ 1,874

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - $ / shares		12 Months Ended
	Mar. 21, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Dividends, Per Share, Declared (in dollars per share)		$ 0.21	$ 0.05	$ 0.18
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.07